Company Description
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also inclu...
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.
Valuation
Price to Sales Ratio
1.42
Enterprise Value to EBITDA
-9.51
Enterprise Value to Sales
2.33
Efficiency
Total Asset Turnover
1.23
Liquidity
Current Ratio
1.83
Quick Ratio
1.71
Cash Ratio
1.18
Profitability
Gross Margin
91.52
Operating Margin
-23.62
Pretax Margin
-30.51
Net Margin
-30.51
Return on Assets
-37.62
Return on Total Capital
-52.16
Capital Structure
Total Debt to Total Assets
187.10
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Mr. George Kelly Martin | 62 | 2020 | President, Chief Executive Officer & Director |
| Mr. Mike Conley | 59 | 2022 | CFO, Treasurer, Chief Accounting Officer & VP |
| Ms. Allison Ross | - | 2020 | Head-Information Technology |
| Dr. Bruce Mitlak | - | 2020 | Chief Medical Officer |
| Mr. Peter A. Schwartzman | - | 2020 | Vice President-Capital, Strategy & Transactions |
Insider Actions
| 03/15/2022 |
Mark Conley VP, Chief Financial Officer |
50,000 | Award at $0 per share. | 0 |
| 02/21/2022 |
George Kelly Martin CEO and President; Director |
75,000 | Award at $0 per share. | 0 |
| 02/21/2022 |
George Kelly Martin CEO and President; Director |
960,000 | Award at $0 per share. | 0 |
| 01/14/2022 |
Chhaya Shah Chief Business Officer |
65,000 | Award at $0 per share. | 0 |
| 01/14/2022 |
Steven Helwig Principal Financial Officer |
15,000 | Award at $0 per share. | 0 |
| 01/14/2022 |
Jean-Pierre Garnier Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
Catherine J. Friedman Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
Danielle Holtschlag Vice President, Sales |
25,000 | Award at $0 per share. | 0 |
| 01/14/2022 |
Willard H. Dere Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
Owen Patrick Hughes Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
Sean E. Murphy Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
Andrew C. von Eschenbach Director |
5,500 | Award at $0 per share. | 0 |
| 01/14/2022 |
A. Machelle Sanders Director |
5,500 | Award at $0 per share. | 0 |
| 01/06/2022 |
Bellevue Asset Management AG |
300,000 | Acquisition at $6.31 per share. | 1,893,000 |
| 01/05/2022 |
Bellevue Asset Management AG |
250,000 | Acquisition at $6.3 per share. | 1,575,000 |
| 12/16/2021 |
Rubric Capital Management LP |
146,685 | Acquisition at $7.07 per share. | 1,037,062 |
| 12/15/2021 |
Rubric Capital Management LP |
180,744 | Acquisition at $6.77 per share. | 1,223,636 |
| 12/14/2021 |
Rubric Capital Management LP |
94,103 | Acquisition at $6.81 per share. | 640,841 |
| 12/13/2021 |
Rubric Capital Management LP |
187,391 | Acquisition at $7.08 per share. | 1,326,728 |
| 12/10/2021 |
Rubric Capital Management LP |
768,171 | Acquisition at $7.18 per share. | 5,515,467 |
MarketWatch News on RDUS
-
Radius Health started at underperform with $16 stock price target at BofA Securities
- Tomi Kilgore
-
Radius Health started at hold with $20 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
How to invest in biotech stocks like a Nobel Prize winner
- Michael Brush
-
Nutrisystem: Starved for Attention
- Barron's Online
-
SEC says companies should brace for comment letters on new revenue rule
- Francine McKenna
-
Activist Elliott Management Weighs Athenahealth
- Barron's Online
-
Jana Partners Sees Sparkle in Tiffany
- Barron's Online
-
Elliott Associates Sees Potential in Advisory Board Co. Sale
- Barron's Online
-
Charting the S&P 500’s approach of the 2016 peak
- Michael Ashbaugh
-
Barrons.com Stock Picks Just Behind Index in ’15
- Barron's Online
-
Biotech Stocks Now Seeing Bullish Signs in the Charts
- Barron's Online
-
Radius Health started at overweight with $88 stock price target at J.P. Morgan
- Tomi Kilgore
-
Amgen vs Radius: Who Will Dominate Bone Density Market?
- Barrons Blogs
-
Barrons.com Stock Picks Handily Beat the Market
- Barron's Online
-
Barrons.com Stock Picks Handily Beat the Market
- Barron's Online
-
Radius Health downgraded to hold from buy at Maxim
- Tomi Kilgore
-
Radius Health stock price target raised to $60 from $50 at Maxim Group
- Tomi Kilgore
-
Radius Health Looks Fully Valued
- Barron's Online
- Loading more headlines...
Other News on RDUS
-
Radius Health (RDUS) Q1 2022 Earnings Call Transcript
- Motley Fool
-
- Edgar Online - (EDG = 10Q, 10K)
-
Radius Health Q1 2022 Earnings Preview
- Seeking Alpha
-
Notable earnings before Thursday's open
- Seeking Alpha
-
Radius Health files sNDA for osteoporosis drug Tymlos in men
- Seeking Alpha
-
Radius Health (RDUS) Q4 2021 Earnings Call Transcript
- Motley Fool
-
- Seeking Alpha
- Loading more headlines...
